OVERVIEW OF AZATHIOPRINE TREATMENT IN MULTIPLE-SCLEROSIS

被引：189

作者：

YUDKIN, PL

ELLISON, GW

GHEZZI, A

GOODKIN, DE

HUGHES, RAC

MCPHERSON, K

MERTIN, J

MILANESE, C

机构：

[1] UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT NEUROL,ST THOMAS ST,LONDON SE1 9RT,ENGLAND

[2] RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND

[3] UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024

[4] MELLEN CTR MULTIPLE SCLEROSIS TREATMENT & RES,CLEVELAND,OH

[5] UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND

[6] THERAPIEZENTRUM BURGAU,BURGAU,GERMANY

[7] IST NEUROCHIRURG C BESTA,I-20133 MILAN,ITALY

[8] CTR STUDI SCLEROSI MULTIPLE,GALLARATE,ITALY

来源：

LANCET | 1991年 / 338卷 / 8774期

关键词：

D O I：

10.1016/0140-6736(91)91909-E

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The efficacy of azathioprine in the treatment of multiple sclerosis was assessed by meta-analysis of the results of all published blind, randomised, controlled trials. 793 patients were enrolled in 5 double-blind and 2 single-blind studies. After 1 year of treatment, the increase in Kurtzke disability status score was no different in treated and control groups, but at 2 years there was a small difference (-0.22; 95% confidence interval [CI] -0.43, 0.003) in favour of azathioprine treatment; this difference was sustained, but not increased, after 3 years. The probability of freedom from any relapse during 1, 2, and 3 years' treatment was significantly greater in the azathioprine-treated group (relative odds over 3 years 1.97; 95% CI 1.27, 3.04), but it is debatable whether the slight clinical benefits of azathioprine outweigh its side-effects.

引用

页码：1051 / 1055

页数：5

共 26 条

[1] THE COMBINATION OF ESTIMATES FROM DIFFERENT EXPERIMENTS
COCHRAN, WG
[J]. BIOMETRICS, 1954, 10 (01) : 101 - 129
[2] A PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-MASKED, VARIABLE DOSAGE, CLINICAL-TRIAL OF AZATHIOPRINE WITH AND WITHOUT METHYLPREDNISOLONE IN MULTIPLE-SCLEROSIS
ELLISON, GW
MYERS, LW
MICKEY, MR
GRAVES, MC
TOURTELLOTTE, WW
SYNDULKO, K
HOLEVOETHOWSON, MI
LERNER, CD
FRANE, MV
PETTLERJENNINGS, P
[J]. NEUROLOGY, 1989, 39 (08) : 1018 - 1026
[3] AN ASSESSMENT OF DISABILITY RATING-SCALES USED IN MULTIPLE-SCLEROSIS
FRANCIS, DA
BAIN, P
SWAN, AV
HUGHES, RAC
[J]. ARCHIVES OF NEUROLOGY, 1991, 48 (03) : 299 - 301
[4] Ghezzi A, 1989, RECENT ADV MULTIPLE
[5] THE EFFICACY OF AZATHIOPRINE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS
GOODKIN, DE
BAILLY, RC
TEETZEN, ML
HERTSGAARD, D
BEATTY, WW
[J]. NEUROLOGY, 1991, 41 (01) : 20 - 25
[6] GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850
[7] INTENSIVE IMMUNOSUPPRESSION IN PROGRESSIVE MULTIPLE-SCLEROSIS - A RANDOMIZED, 3-ARM STUDY OF HIGH-DOSE INTRAVENOUS CYCLOPHOSPHAMIDE, PLASMA-EXCHANGE, AND ACTH
HAUSER, SL
DAWSON, DM
LEHRICH, JR
BEAL, MF
KEVY, SV
PROPPER, RD
MILLS, JA
WEINER, HL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 308 (04) : 173 - 180
[8] TREATMENT OF CHRONIC PROGRESSIVE FORM OF MULTIPLE-SCLEROSIS WITH A COMBINATION OF CYCLOPHOSPHAMIDE AND PREDNISONE
HOMMES, OR
PRICK, JJG
LAMERS, KJB
[J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 1975, 78 (01) : 59 - 72
[9] INCIDENCE OF CANCER IN RHEUMATOID-ARTHRITIS AND OTHER DISORDERS AFTER IMMUNOSUPPRESSIVE TREATMENT
KINLEN, LJ
[J]. AMERICAN JOURNAL OF MEDICINE, 1985, 78 (1A) : 44 - 49
[10] THE DISABILITY STATUS SCALE FOR MULTIPLE-SCLEROSIS - APOLOGIA PRO DSS SUA
KURTZKE, JF
[J]. NEUROLOGY, 1989, 39 (02) : 291 - 302

← 1 2 3 →